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Oxycodone is commonly used to treat severe pain in adults and children. It is extensively
metabolized in the liver in adults, but the maturation of metabolism is not well understood.
Our aim was to study the metabolism of oxycodone in cryopreserved human hepato-
cytes from different age groups (3 days, 2 and 5months, 4 years, adult pool) and predict
hepatic plasma clearance of oxycodone using these data. Oxycodone (0.1, 1, and 10μM)
was incubated with hepatocytes for 4 h, and 1μM oxycodone also with CYP3A inhibitor
ketoconazole (1μM). Oxycodone and noroxycodone concentrations were determined at
several time points with liquid chromatography–mass spectrometry. In vitro clearance of
oxycodone was used to predict hepatic plasma clearance, using the well-stirred model
and published physiological parameters. Noroxycodone was the major metabolite in all
batches and ketoconazole inhibited the metabolism markedly in most cases. A clear cor-
relation between in vitro oxycodone clearance and CYP3A4 activity was observed. The
predicted hepatic plasma clearances were typically much lower than the published median
total plasma clearance from pharmacokinetic studies. The data suggests that there are
no children-speciﬁc metabolites of oxycodone. Moreover, CYP3A activity seems to be
the major determinant in metabolic clearance of oxycodone regardless of age group or
individual variability in hepatocyte batches.
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INTRODUCTION
Oxycodone (7,8-dihydro-14-hydroxycodeinone) is a commonly
prescribed opioid for severe pain, and during the last years its
use has surpassed that of morphine in several countries (Interna-
tional Narcotics Control Board, 2010). Oxycodone is extensively
metabolized in the liver and only ca. 10% of the dose is excreted
unchanged in urine in adults (Pöyhiä et al., 1992; Kirvelä et al.,
1996; Lalovic et al., 2006), but the majority of the metabolites
are excreted in urine (Lalovic et al., 2006). The principal meta-
bolic pathway is CYP3A-mediated N -demethylation to noroxy-
codone (Lalovic et al., 2004, 2006). Another important route is
CYP2D6-mediated O-demethylation to oxymorphone. A large
portion of noroxycodone and oxymorphone is further metabo-
lized or conjugated, e.g., noroxymorphone is formed mainly via
O-demethylation of noroxycodone by CYP2D6. Oxymorphone
and noroxymorphone are active metabolites, but they probably
do not contribute markedly to the central opioid effects since their
plasma concentrations are signiﬁcantly lower than that of parent
compound (Heiskanen et al., 1998; Lalovic et al., 2006; Lemberg
et al., 2010). Furthermore, these metabolites are less lipophilic
than oxycodone, a characteristic that may limit their uptake into
the brain (Lalovic et al., 2006).
There seems to be nomajor differences in the pharmacokinetics
of oxycodone between children and adults (Olkkola et al., 1994;
Kokki et al., 2004, 2006), and a weight-based dose can be used
for children and infants aged over 6months (El-Tahtawy et al.,
2006). On the contrary, the dose titration for infants younger than
6months must be cautious because the inter-individual variation
in the clearance and elimination of oxycodone is signiﬁcant and
the clearance could be very low in some of the youngest subjects
(Pokela et al., 2005).
Although oxycodone has been in clinical use for over 90 years
(Falk, 1917), its metabolic pathways in infants and children are not
sufﬁciently understood. In addition, FDA guidance recommends
to study pharmacokinetic phenomena also in pediatric models
such as in vitro metabolic studieswith pediatric preparations (FDA
Guidance for Industry, 1998). In the present study, we measured
the maturation of oxycodone metabolism in vitro using human
hepatocytes from different age groups. In addition, we predicted
the hepatic plasma clearance of oxycodone based on these data
and estimated the accuracy of the prediction.
MATERIALS AND METHODS
MATERIALS
Oxycodone, noroxycodone, oxymorphonem, and noroxymor-
phone were obtained from Cerilliant (Round Rock, TX, USA),
and ketoconazole from Sigma (St. Louis, MO, USA). High-
performance liquid chromatographic (HPLC)grademethanol and
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acetonitrile were obtained from Merck (Darmstadt, Germany).
Ammonia was obtained from BDH Laboratory Supplies (Poole,
UK). Other chemicals were obtained from Sigma (St. Louis, MO,
USA) and were of the highest purity available. Water (ultra pure,
18.2MΩ) was freshly preparedwithDirect-Q3 puriﬁcation system
(Millipore Oy, Espoo, Finland). Human cryopreserved hepato-
cytes were obtained from BD Biosciences (Franklin Lakes, NJ,
USA), Celsis (Brussels, Belgium), and Invitrogen (Carlsbad, CA,
USA). The donors were 3-day, 5-month, and 4-year-old Caucasian
females, a 2-month-old Caucasian male, and a pool of 20 adults
(pools of 10 women and 10 men were combined), mostly Cau-
casians. The 3-day-old donor had received phenobarbital that is a
potent inducer of CYP3A and several other CYP enzymes.
IN VITRO INCUBATION OF OXYCODONE WITH CRYOPRESERVED
HEPATOCYTES
Oxycodone concentrations in the incubations (0.1–10μM) were
chosen to be close to the clinical plasma concentrations of oxy-
codone (typically <0.3μM) and much lower than the mean Km
values for CYP3A-mediated noroxycodone formation (600μM)
and CYP2D6-mediated oxymorphone formation (130μM) in
human liver microsomes (Lalovic et al., 2004). The hepatocytes
were thawed and suspended according to Celsis protocol. Brieﬂy,
tubeswere rapidly thawed,cells suspended intoCelsis InVitroGRO
HT-medium, and centrifuged (50× g, 5min). Cells were resus-
pended into Celsis InVitro GRO HI-medium. The cell density and
viability were determined by trypan blue exclusion method. The
viabilities of the individual donor cells varied from 75 to 98%.
Cells were diluted into InVitro GRO HI to two million viable cells
per milliliter. Oxycodone was dissolved into DMSO at 2mM con-
centration and diluted into InVitro GRO HI to concentrations 0.2,
2, and 20μM. Oxycodone solution (175μl) was applied to 48-well
tissue culture plate in a single well. An equal volume of hepato-
cyte suspension was added to the well yielding ﬁnal hepatocyte
concentration of one million viable cells per milliliter in 0.1, 1,
or 10μM oxycodone solution. Plates were incubated at 37˚C in
humidiﬁed CO2-incubator with 600 rpm orbital stirring. Samples
of 50μl were taken at 0, 30, 60, 120, and 240min from the well
and suspended into 50μl of cold acetonitrile. The incubations
with 1μM oxycodone were conducted also with 1μM ketocona-
zole. Two replicates of each experiment were conducted. Samples
were stored at −20˚C until analysis.
ESTIMATION OF OXYCODONE FREE FRACTION IN HEPATOCYTE
INCUBATION
The passive accumulation into hepatocytes was studied with cells
that were kept overnight at 22˚C. Oxycodone at 0.1, 1, and 10μM
concentration in the incubation medium was incubated with
one million cells per milliliter for 4 h with continuous shaking
(100 rpm) at 37˚C in a RED equilibrium dialysis device (Lin-
den Bioscience, MA, USA), using 350μl of 100mM phosphate
buffered saline (PBS) as a receiver side solution. The incubation
was conducted in a Heidolph Titramax 1000 incubation cabin
(Heidolph Instruments GmbH & Co. KG, Schwabach, Germany).
After incubation, both sides of the dialysis chamber were sam-
pled, and matrices made similar by adding blank cell suspension
to buffer sample and buffer to cell suspension sample. Acetonitrile
was added to precipitate proteins, samples were centrifuged, and
supernatants were analyzed by liquid chromatography–mass spec-
trometry (LC–MS). The free fraction of oxycodone in the hepa-
tocyte incubation (fuinc) was calculated directly from the peak
area ratios measured for each phase: fuinc = peak area in receiver
sample/peak area in donor sample.
LIQUID CHROMATOGRAPHIC–MASS SPECTROMETRIC ANALYSIS
The hepatocyte incubation samples were thawed at 22˚C, shaken,
and centrifuged for 10min at 16,100× g (Eppendorf 5415D,
Eppendorf AG, Hamburg, Germany). The supernatants from 0.1
to 1μM oxycodone incubations were diluted with water to 1:2 and
those from 10μM oxycodone incubations to 1:5 before analyses.
For identiﬁcation and quantitation of oxycodone and its metabo-
lites, a Waters Acquity ultra-performance liquid chromatographic
(UPLC) system with an autosampler, a vacuum degasser, and a
column oven was used. The analytical column used was a Waters
BEH C18 (2.1mm× 50mm, 1.7μm; Waters Corporation, Mil-
ford, MA, USA). The eluents were 0.02% ammonia (A, pH 9.8)
and acetonitrile (B). A gradient elution with a proﬁle 5% B – 5%
B – 35% B – 85% B in 0, 1, 3, 3.5min was employed, followed by
column equilibration for 2min. The ﬂow rate was 0.5ml/min and
the column oven temperature was 35˚C. Injection volume of 4 μl
was used. LC/time-of-ﬂight (TOF)–MS data were acquired with
a Waters LCT Premier XE TOF–MS equipped with a LockSpray
electrospray ionization source. A positive ionization mode of elec-
trospray was used with a capillary voltage of 2800V and a cone
voltage of 60V. W-mode ion optics and dynamic range enhance-
ment (DRE) option were used. Aperture 1 voltages of 5 and 65V
were used to obtain molecular ion data and in-source fragment
ion data, respectively. Nitrogen was used as both desolvation and
nebulizing gases with ﬂow rates of 800 and 100 l/h, respectively.
Desolvation temperature was set to 350˚C and source gas to 150˚C.
The mass range of m/z 100–750 was acquired with an acquisi-
tion time of 150ms. The mass spectrometer and UPLC system
were operated under Micromass MassLynx 4.1 software (Waters
Corporation, Milford, MA, USA). Leucine enkephalin was used
as lock mass compound ([M +H]+ m/z 556.2771) for accurate
mass measurements. Metabolites were mined from the data by
using Metabolynx XS subroutine of Masslynx-software, employ-
ing dealkylation tool and“chemically intelligent”(structure based)
mass defect ﬁltering with a 50-mDa tolerance window. The real
positives (metabolites) and their identiﬁcations were conﬁrmed
from the data manually. In quantitation, ion chromatograms with
50mDa window were used.
Calibration curve with oxycodone was used for quantitation of
oxycodone and its metabolites M1–M3 and M5–M8. Correlation
coefﬁcient R2 was 0.987 for the range 1–2000 nM, and back cal-
culated accuracies were 84–103% in each concentration level, and
overall snedecor-precision was 14.2% (n = 2 at each concentra-
tion). For noroxycodone (M4), a calibration curvewith correlation
coefﬁcient R2 = 0.994 was obtained for the range 2–2000 nM, the
back calculated accuracies were 88–107% in each concentration
level, and the overall snedecor-precision was 9.7%.
For analysis of oxycodone samples from hepatocyte bind-
ing experiments, a Waters Alliance 2695 HPLC with a col-
umn oven and an autosampler was used together with Waters
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XBridge C18 (2.1mm× 50mm, 3.5μm) column+Phenomenex
C18 (2.0mm× 4mm, 3.0μm) precolumn. The eluents were
0.02% ammonia (A, pH 9.8) and acetonitrile (B). A gradient elu-
tion with proﬁle 5% B – 85% B – 85% B in 0 – 1 – 3min was
employed, followed by column equilibration for 3min. The ﬂow
rate was 0.4ml/min and the column oven temperature was 35˚C.
Injection volume of 5 μl was used. Data was acquired usingWaters
Quattro Micro triple quadrupole mass spectrometer with z-spray
electrospray ion source. A capillary voltage of 1400V and cone
voltage of 28V were used. Nitrogen was used as both desolvation
and nebulizing gases with ﬂow rates of 800 and 100 l/h, respec-
tively. Desolvation temperature was set to 350˚C and source gas
to 150˚C. Multiple reaction monitoring with positive ion mode
was used with transition m/z 316> 298 and collision energy
of 19 eV. Argon was used as a collision gas at 3.8× 10–3 mbar
pressure.
CALCULATION OF IN VITRO CLEARANCE
Themeasuredoxycodone concentrations (C t; nM) from thedupli-
cate experiment at different sampling times (t ; min) were ﬁtted
into the exponential decay function [C t =C0 EXP(−kt )] to get
estimates for the concentration at time zero (C0; nM) and elimina-
tion rate constant (k; min−1) using WinNonlin software (version
5.2.1, Pharsight, Mountain View, CA, USA). Apparent in vitro
clearance (μl/min∗106 cells)was calculated bymultiplying the rate
constant with the initial incubation volume (350μl) and dividing
the product by 0.35 since there were initially 0.35 × 106 cells in
each well. The subsequent samples from the well did not change
the ratio of the incubation volume to the number of cells. In vitro
clearance based on unbound drug concentration (in vitro CLu)
was calculated by diving the apparent clearance by fuinc.
PREDICTION OF HEPATIC PLASMA CLEARANCE
The weight and height of the donor was estimated to be the
average value for particular age and gender (Kuczmarski et al.,
2002; Valentin, 2003). The anatomical and physiological parame-
ters were calculated using the procedures by Johnson et al. (2006)
with minor modiﬁcations. The body surface area (BSA) was cal-
culated from the weight and height using the equation by Haycock
et al. (1978) when the weight was below 15 kg and the equation
fromDuBois andDuBois (1916) in other cases. The cardiac output
was calculated for children from BSA using the equation 3 in John-
son et al. (2006), for the adult pool the average of male and female
values in Valentin (2003) was used. The total hepatic blood ﬂow
(QH,B) was estimated to be 27% of cardiac output based on adult
data (Valentin, 2003; Johnson et al., 2006). The liver volume (l)
was calculated as 0.722∗BSA1.176 and it was multiplied with liver
density (1.08 kg/l) to get liver mass (Johnson et al., 2005). The total
number of hepatocytes was obtained by multiplying the liver mass
with the recommended hepatocellularity of 99× 106 cells in gram
of liver (Barter et al., 2007). Intrinsic in vivo clearance in the liver
based on unbound drug concentration (CLuint,H) was obtained by
multiplying intrinsic in vitro CLu with the total number of hepa-
tocytes. The fraction unbound of oxycodone in plasma (fu) was
estimated to be 0.59 (the average from the studies by Leow et al.,
1993; Pöyhiä and Seppälä, 1994). The blood to plasma concen-
tration ratio (CB/CP) was estimated to be 1, but also the value in
rats (1.3) in Boström et al. (2006) was tested. The hepatic plasma
clearance (CLH) of oxycodonewas estimated using thewell-stirred
model (Yang et al., 2007):
CLH = QH,B × fu × CLuint,H
QH,B + fu×CLuint,HCB/CP
RESULTS
FORMATION OF METABOLITES
Eight oxycodone-related metabolites were observed (Figure 1).
All of these metabolites were observed in cells from 4-year-old
donor and in pooled adult cells, whereas cells from 3 days, 2 and 5-
months-old donors contained ﬁve to seven metabolites (Table 1).
No metabolites speciﬁc to a single age group only were observed.
The detected metabolites were identiﬁed based on the mass spec-
tral accurate mass and fragment ion data and retention times.
Due to low abundance of metabolites M1 and M3, fragment ion
FIGURE 1 | Proposed in vitro metabolic pathway of oxycodone in
hepatocyte incubations.
Table 1 | Qualitative metabolite profiles from hepatocyte incubations.
3 days 2months 5months 4 years Adult
M1 + − − + +
M2 + + + + +
M3 + + − + +
M4 + + + + +
M5 + + − + +
M6 + + + + +
M7 + + + + +
M8 − + + + +
Tentative structures of the metabolites are presented in Figure 1.
+, Metabolite detected; −, metabolite not detected.
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data was not observed and therefore only tentative identiﬁcations
as changes in molecular formula with respect to oxycodone were
obtained.
Quantitative analytical results revealed that noroxycodone was
a major metabolite in all hepatocyte batches (Figure 2). Typically,
theparent compoundandnoroxycodone comprisemore than75%
of drug related material in the last sampling point. Ketoconazole
reduced but not completely blocked the conversion of oxycodone
to noroxycodone. This suggests that CYP3A is strongly involved
in this demethylation reaction in vitro.
IN VITRO CLEARANCE
The observed free fractions of oxycodone in the hepatocyte incu-
bations (fuinc) were 0.93, 0.86, and 0.88 at 0.1, 1, and 10 μM
oxycodone, respectively. The average value (0.9) was used in the
calculation of in vitro clearance based on unbound concentra-
tion. In vitro clearance of oxycodone varied in different hepatocyte
batches (Figure 3). The highest clearance was observed in the
hepatocytes from the 3-day-old donor who had received pheno-
barbital. In the 3-day, 2-month, and 4-year batches the clearance
was fairly constant at different oxycodone concentrations, indi-
cating that there was no clear saturation of metabolism at the
highest concentration (10μM). In the adult batch the clearance
increased with the concentration for unknown reasons. For the
5-month batch, the clearance could not be estimated at con-
centrations below 10μM since the 95% conﬁdence interval for
the estimated elimination rate constant included the value zero.
CYP3A inhibitor ketoconazole reduced the clearance markedly in
the 3-day, 4-year, and adult batches, but not in the 2-month batch
(Figure 3).
CORRELATION ANALYSIS
There was a statistically signiﬁcant positive correlation (Pear-
son correlation 0.95, p = 0.012, R2 = 0.91) between the observed
in vitro CLu and reported CYP3A4 activity of different cell batches
(Table 2). The correlation of in vitro CLu to the reported CYP2D6
is ambiguous because of two different substrates that has been
used in hepatocyte lot characterization.However, there seems to be
no correlation with observed CLu and CYP2D6 activity (Pearson
correlation −0.17, p = 0.78, R2 = 0.03).
PREDICTION OF HEPATIC PLASMA CLEARANCE
In the prediction of hepatic plasma clearance, the intrinsic in vitro
clearance (in vitro CLuint) was taken from the incubation with
1μM oxycodone, except for the 5-month batch the value from
10μM oxycodone was used (Table 3). The predicted hepatic
clearance was in most cases markedly lower than the median
total plasma clearance observed in pharmacokinetic studies, being
FIGURE 2 | Fractional concentrations of oxycodone (white bars) and noroxycodone (black bars) at the last time point (4 h) in hepatocyte incubations
from 3day (A), 2month (B), 5month (C), 4 year (D), and adult (E) donors. Bars represent mean±SD (single experiment in duplicate). KTZ, ketoconazole.
Frontiers in Pharmacology | Drug Metabolism andTransport January 2012 | Volume 2 | Article 87 | 4
Korjamo et al. Oxycodone metabolism in age groups
either close to the minimum total clearance (2months and adult
pool) or even lower than that (5months and 4 years). The excep-
tion was the batch from the 3-day-old donor. In this case the
predicted hepatic clearance was slightly higher than the observed
median total clearance. When the calculations for the adult were
made using in vitro CLu from the incubation with 10μM oxy-
codone [6.6μl/(min∗106 cells)], in vivo CLuint,H of 1000ml/min
andpredicted hepatic clearance of 6.5ml/(min∗kg)were obtained.
The latter is one half of the observed median total clearance.
DISCUSSION
In this study, we evaluated an in vitro to in vivo extrapolation
method to estimate the maturation of oxycodone metabolism in
humans.Generally, the ontogenyof hepatic clearancepathways has
been studied actively and several methods have been developed for
FIGURE 3 | In vitro clearance of oxycodone based on unbound
concentration (in vitro CLu) in cryopreserved human hepatocyte at
0.1μM (white bars), 1μM (gray bars), 10μM (black bars), or 1μM in
the presence of ketoconazole (hatched bars).
the prediction of hepatic clearance in infants and children (Alcorn
and McNamara, 2002; Edginton et al., 2006; Johnson et al., 2006).
In these methods the activity of each metabolic enzyme vs. age
is described mathematically based on the available data on the
expression and activity (in vitro and in vivo clearance of various
substrates) of the enzyme. The input data needed are either the
pharmacokinetic parameters of the drug in adults or Michaelis–
Menten parameters of the involved enzymes from in vitro studies.
Our approach was to utilize hepatocyte preparations from dif-
ferent age groups to study age-dependent metabolism directly
in vitro.
The metabolism in different age groups was qualitatively fairly
similar (Figure 1; Table 1). Worth noticing is that the known oxy-
codone metabolites oxymorphone and noroxymorphone (Lalovic
et al., 2004, 2006) were not detected in the samples, even thought
the oxymorphone was detected as a glucuronide conjugated form
(M7), and possibly also in M6 and M8, for which the demethyla-
tion site remainedunclear.One reason for thismay be the observed
poor stability of these compounds in incubation medium since
the prepared oxymorphone and noroxymorphone standard sam-
ples were found to degradate very rapidly in used autosampler
conditions (2μM concentration both the substances disappeared
completely in 12 h).
The importance of CYP3A in the metabolism of oxycodone
in the hepatocytes was supported by the data. Noroxycodone,
known to be formed by CYP3A4 and CYP3A5 (Lalovic et al.,
2004), was a major metabolite in all batches. CYP3A inhibitor
ketoconazole inhibited the metabolism of oxycodone and forma-
tion of noroxycodone in most cases. There was also a positive
correlation between oxycodone clearance and CYP3A4 activity
but not CYP2D6 activity. The CYP3A-mediated noroxycodone
formationhas been shown tobe eightfoldwith respect toCYP2D6-
mediated oxymorphone formation in human liver microsomes
(Lalovic et al., 2004). Also, urinary excretion data have revealed
that CYP3A-mediatedN -demethylation is the principalmetabolic
pathway in adults (Kirvelä et al., 1996; Lalovic et al., 2006).
Table 2 | Experimentally measured in vitro clearance of oxycodone and reported CYP3A4 and CYP2D6 activities in hepatocyte batches used in
the study.
Donor age 3days 2months 5months 4 years Adult pool
Supplier BD Biosciences Invitrogen BD Biosciences BD Biosciences Celsis
In vitro CLu 9.8 2.2 0.9 2.1 4.2
Activity vs. adult batch 2.3 0.5 0.2 0.5 1.0
CYP3A4 activity1 790 212 63 310 210–2802
Activity vs. adult batch 3.2 0.9 0.3 1.3 1.03
CYP2D6 activity4 15 – 6.7 30 -
Activity vs. 3-day batch 1.0 0.4 2.0
CYP2D6 activity5 29 15.5
Activity vs. adult batch 1.9 1.0
In vitro CLu (μl/min/106 cells) obtained from the incubation with 1μM oxycodone, except for the 5-month batch from 10μM oxycodone. All the CYP activities
were provided by the supplier in pmol/(min∗106 cells): 16β-hydroxytestosterone formation using 200μM testosterone; 2estimated range for incubation with 200μM
testosterone was calculated by multiplying the supplier value (161) obtained with 50μM testosterone (60min) by 1.3–1.75 based on the Hill equations constants
(S50 =25–50μM; n=1.45; Kenworthy et al., 2001; Brown et al., 2007); 3normalised using average value of 245; 41′-hydroxybufuralol formation using 25μM bufuralol;
5dextrorphan formation using 15μM dextromethorphan (2month) or 8μM dextromethorphan (adult).
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Table 3 | Prediction of hepatic plasma clearance of oxycodone using in vitro clearance in hepatocytes and physiological parameters.
Donor age 3days 2months 5months 4 years Adult pool
Gender Female Male Female Female Female+male
Weight (kg) 3.4 5.3 6.7 16 67
Height (cm) 49 58 63 101 170
Body surface area (m2) 0.22 0.3 0.35 0.66 1.78
Cardiac output (ml/min) 510 710 840 1980 6200
Hepatic blood ﬂow (ml/min) 140 190 230 530 1670
Liver mass (g) 130 190 230 480 1540
Total hepatocytes (106) 13,000 19,000 23,000 48,000 152,000
In vitro CLuint1 [μl/(min*106 cells)] 9.8 2.2 0.9 2.1 4.2
In vivo CLuint,H (ml/min) 127 42 20 99 644
Predicted ClH
ml/min 49 22 11 53 310
ml/(min*kg) 14 4.1 1.7 3.3 4.6
Observed total CL2 [ml/(min*kg)] 9.9 (2.3–17)3 16 (3.7–80)4 16 (3.7–80)4 15 (8.5–21)5 12 (4.4–34)6
1In vitro CLuint from the incubation with 1μM oxycodone, except for the 5-month batch from 10μM oxycodone; 2total plasma clearance after intravenous administra-
tion: median (range); 3Infants younger than 1week (Pokela et al., 2005); 4infants aged 1.5–6months (Pokela et al., 2005); 5mean (range) in children aged 2–10 years
(Olkkola et al., 1994; Kokki et al., 2004); 6healthy volunteers and cancer patients aged 19–71 years (Pöyhiä et al., 1991; Leow et al., 1992; Takala et al., 1997).
In vitro clearance of oxycodone in the hepatocytes was used
to predict hepatic plasma clearance. In the adults, the median
hepatic plasma clearance is ca. 11ml/(min∗kg) based on the ﬁnd-
ings that total plasma clearance is ca. 12ml/(min∗kg; Table 3)
and ca. 10% of the dose is excreted unchanged in urine (Pöyhiä
et al., 1992; Kirvelä et al., 1996; Lalovic et al., 2006). The pre-
dicted hepatic clearance using pooled adult hepatocytes with 1 and
10μM oxycodone were ca. 40 and 60% of the observed median
value. Earlier, Lalovic et al. (2004) reported a mean intrinsic clear-
ance of 12μl/min/mg microsomal protein and negligible binding
in human liver hepatocytes. Thus, an intrinsic in vivo clearance of
590 or 740ml/min is extrapolated (methods of Barter et al., 2007;
Hallifax and Houston, 2009); which are close to our value at 1μM
oxycodone (644ml/min; Table 3).
The predicted plasma clearances obtained with hepatocytes
from individual infants and children were signiﬁcantly lower than
the observed median total plasma clearance, except for the 3-day-
old donor. The hepatic plasma clearance of oxycodone in infants
and children is not known accurately since the urinary excretion
of oxycodone and its metabolites has not been reported. However,
plasma concentrations of oxycodone,noroxycodone, and oxymor-
phone have been determined in children aged 0.5–8 years after
buccal and sublingual administration (Kokki et al., 2006). In these
children theAUCratio of noroxycodone tooxycodonewas approx-
imately as high and AUC ratio of oxymorphone to oxycodone as
low as in adults after oral administration. This suggests that in
these children the metabolic clearance and especially the role of
CYP3A is as important as in adults. There are no pharmacoki-
netic data on the metabolism of oxycodone in infants aged below
0.5 years since only plasma concentrations of oxycodone have been
determined (Pokela et al., 2005).
Under-prediction of hepatic clearance based on in vitro data
from hepatocyte and microsome incubations is common (Hal-
lifax and Houston, 2009; Foster et al., 2011). Compounds with
low metabolic clearance in vitro produce often poor in vitro
in vivo extrapolations based on parent compound metabolic dis-
appearance (Chiba et al., 2009) partly because active uptake to
liver can affect in vivo clearance but is not evident from typical
in vitro stability results (Soars et al., 2007). Oxycodone transport
across blood–brain barrier is partly dependent on some organic
cation transporter (Okura et al., 2008) and P-glycoprotein can
also transport oxycodone (Hassan et al., 2007). Therefore, active
uptake to liver can cause the observed under-prediction of oxy-
codone clearance since only rate of metabolism was measured
in vitro.
In the present study, cryopreserved hepatocytes from different
age groups were used to study the maturation of the drug metab-
olism. These studies reveal that similar metabolites are formed in
children and adults. For oxycodone, this is important informa-
tion since knowledge on in vivo metabolite proﬁles in youngest
infants is missing (Pokela et al., 2005). The data suggests that
the major determinant of oxycodone clearance in all age groups
is CYP3A activity. Therefore, oxycodone clearance may follow
general CYP3A ontogeny and possible inter-individual variability
within age groups.
ACKNOWLEDGMENTS
We would like to thank PhD Ilpo Rasanen for helpful discussions.
REFERENCES
Alcorn, J., and McNamara, P. J.
(2002). Ontogeny of hepatic
and renal systemic clear-
ance pathways in infants: part
II. Clin. Pharmacokinet. 41,
1077–1094.
Barter, Z. E., Bayliss, M. K., Beaune,
P. H., Boobis, A. R., Carlile, D. J.,
Edwards, R. J., Houston, J. B., Lake,
B. G., Lipscomb, J. C., Pelkonen,
O. R., Tucker, G. T., and Rostami-
Hodjegan, A. (2007). Scaling factors
for the extrapolationof in vivometa-
bolic drug clearance from in vitro
data: reaching a consensus on val-
ues of human microsomal pro-
tein and hepatocellularity per gram
of liver. Curr. Drug Metab. 8,
33–45.
Frontiers in Pharmacology | Drug Metabolism andTransport January 2012 | Volume 2 | Article 87 | 6
Korjamo et al. Oxycodone metabolism in age groups
Boström, E., Simonsson, U. S., and
Hammarlund-Udenaes, M. (2006).
In vivo blood-brain barrier trans-
port of oxycodone in the rat:
indications for active inﬂux and
implications for pharmacoki-
netics/pharmacodynamics. Drug
Metab. Dispos. 34, 1624–1631.
Brown, H. S., Grifﬁn, M., and Houston,
J. B. (2007). Evaluation of cryop-
reserved human hepatocytes as an
alternative in vitro system to micro-
somes for the prediction of meta-
bolic clearance. Drug Metab. Dispos.
35, 293–301.
Chiba, M., Ishii, Y., and Sugiyama, Y.
(2009). Prediction of hepatic clear-
ance in human from in vitro data for
successful drug development. AAPS
J. 11, 262–276.
DuBois, D., and DuBois, E. F. (1916). A
formula to estimate the approximate
surface area if height and weight
be known. Arch. Intern. Med. 17,
863–871.
Edginton, A. N., Schmitt, W., Voith, B.,
and Willmann, S. (2006). A mech-
anistic approach for the scaling of
clearance in children. Clin. Pharma-
cokinet. 45, 683–704.
El-Tahtawy, A., Kokki, H., and Reiden-
berg, B. E. (2006). Population phar-
macokinetics of oxycodone in chil-
dren 6 months to 7 years old. J. Clin.
Pharmacol. 46, 433–442.
Falk, E. (1917). Eukodal, ein neues
narkotikum. Munch. Med. Wochen-
schr. 20, 381–384.
FDA Guidance for Industry. (1998).
General Considerations for Pediatric
Pharmacokinetic Studies for Drugs
and Biological Products. Rockville:
Food and Drug Administration.
Foster, J. A., Houston, J. B., and Hal-
lifax, D. (2011). Comparison of
intrinsic clearances in human liver
microsomes and suspended hepa-
tocytes from the same donor liv-
ers: clearance-dependent relation-
ship and implications for prediction
of in vivo clearance. Xenobiotica 41,
124–136.
Hallifax, D., and Houston, J. B.
(2009). Methodological uncertainty
in quantitative prediction of human
hepatic clearance from in vitro
experimental systems. Curr. Drug
Metab. 10, 307–321.
Hassan, H. E., Myers, A. L., Lee,
I. J., Coop, A., and Eddington,
N. D. (2007). Oxycodone induces
overexpression of P-glycoprotein
(ABCB1) and affects paclitaxel’s tis-
sue distribution in Sprague Dawley
rats. J. Pharm. Sci. 96, 2494–2506.
Haycock, G. B., Schwartz, G. J., and
Wisotsky, D. H. (1978). Geometric
method for measuring body surface
area: a height-weight formula vali-
dated in infants, children,and adults.
J. Pediatr. 93, 62–66.
Heiskanen, T., Olkkola, K. T., and
Kalso, E. (1998). Effects of block-
ing CYP2D6 on the pharmacokinet-
ics and pharmacodynamics of oxy-
codone. Clin. Pharmacol. Ther. 64,
603–611.
International Narcotics Control Board.
(2010). Narcotic Drugs: Estimated
World Requirements for 2010; Sta-
tistics for 2008. New York: United
Nations.
Johnson, T. N., Rostami-Hodjegan, A.,
and Tucker, G. T. (2006). Prediction
of the clearance of eleven drugs and
associated variability in neonates,
infants and children. Clin. Pharma-
cokinet. 45, 931–956.
Johnson, T. N., Tucker, G. T., Tan-
ner, M. S., and Rostami-Hodjegan,
A. (2005). Changes in liver vol-
ume from birth to adulthood: a
meta-analysis. Liver Transpl. 11,
1481–1493.
Kenworthy,K. E., Clarke, S. E.,Andrews,
J., and Houston, J. B. (2001). Mul-
tisite kinetic models for CYP3A4:
simultaneous activation and inhibi-
tion of diazepam and testosterone
metabolism. DrugMetab. Dispos. 29,
1644–1651.
Kirvelä, M., Lindgren, L., Seppälä, T.,
and Olkkola, K. T. (1996). The phar-
macokinetics of oxycodone in ure-
mic patients undergoing renal trans-
plantation. J. Clin. Anesth. 8, 13–18.
Kokki, H., Rasanen, I., Laisalmi, M.,
Lehtola, S., Ranta, V. P., Vanamo, K.,
and Ojanperä, I. (2006). Compari-
son of oxycodone pharmacokinetics
after buccal and sublingual admin-
istration in children. Clin. Pharma-
cokinet. 45, 745–754.
Kokki, H., Rasanen, I., Reinikainen, M.,
Suhonen, P., Vanamo, K., and Ojan-
perä, I. (2004). Pharmacokinetics of
oxycodone after intravenous, buccal,
intramuscular and gastric adminis-
tration in children. Clin. Pharma-
cokinet. 43, 613–622.
Kuczmarski, R. J., Ogden, C. L., and
Guo, S. S., Grummer-Strawn, L. M.,
Flegal,K.M.,Mei,Z.,Wei,R.,Curtin,
L. R., Roche, A. F., and Johnson, C.
L. (2002). 2000 CDC growth charts
for the United States: methods and
development. Vital Health Stat. 11,
1–190.
Lalovic, B., Kharasch, E., Hoffer, C.,
Risler, L., Liu-Chen, L. Y., and
Shen, D. D. (2006). Pharmacoki-
netics and pharmacodynamics of
oral oxycodone in healthy human
subjects: role of circulating active
metabolites. Clin. Pharmacol. Ther.
79, 461–479.
Lalovic, B., Phillips, B., Risler, L.
L., Howald, W., and Shen, D. D.
(2004). Quantitative contribution of
CYP2D6 and CYP3A to oxycodone
metabolism in human liver and
intestinal microsomes. Drug Metab.
Dispos. 32, 447–454.
Lemberg, K. K., Heiskanen, T. E., Neu-
vonen, M., Kontinen, V. K., Neuvo-
nen,P. J.,Dahl,M. L., andKalso,E.A.
(2010). Does co-administration of
paroxetine change oxycodone anal-
gesia: an interaction study in chronic
pain patients. Scand. J. Pain 1,24–33.
Leow, K. P., Smith, M. T., Williams,
B., and Cramond, T. (1992). Single-
dose and steady-state pharmacoki-
netics and pharmacodynamics of
oxycodone in patients with cancer.
Clin. Pharmacol. Ther. 52, 487–495.
Leow, K. P.,Wright, A. W., Cramond, T.,
and Smith, M. T. (1993). Determi-
nation of the serum protein binding
of oxycodone and morphine using
ultraﬁltration. Ther. Drug Monit. 15,
440–447.
Okura, T., Hattori, A., Takano, Y.,
Sato, T., Hammarlund-Udenaes, M.,
Terasaki, T., and Deguchi, Y. (2008).
Involvement of the pyrilamine
transporter, a putative organic
cation transporter, in blood-brain
barrier transport of oxycodone.
Drug Metab. Dispos. 36, 2005–2013.
Olkkola,K.T.,Hamunen,K.,Seppälä,T.,
and Maunuksela, E. L. (1994). Phar-
macokinetics and ventilatory effects
of intravenous oxycodone inpostop-
erative children. Br. J. Clin. Pharma-
col. 38, 71–76.
Pokela, M. L., Anttila, E., Seppälä, T.,
and Olkkola, K. T. (2005). Marked
variation in oxycodone pharmaco-
kinetics in infants. Paediatr. Anaesth.
15, 560–565.
Pöyhiä, R., Olkkola, K. T., Seppälä, T.,
and Kalso, E. (1991). The phar-
macokinetics of oxycodone after
intravenous injection in adults. Br.
J. Clin. Pharmacol. 32, 516–518.
Pöyhiä, R., and Seppälä, T. (1994).
Liposolubility and protein binding
of oxycodone in vitro. Pharmacol.
Toxicol. 74, 23–27.
Pöyhiä, R., Seppälä, T., Olkkola, K. T.,
and Kalso, E. (1992). The phar-
macokinetics and metabolism of
oxycodone after intramuscular and
oral administration to healthy sub-
jects. Br. J. Clin. Pharmacol. 33,
617–621.
Soars, M. G., Grime, K., Sproston, J. L.,
Webborn,P. J., andRiley,R. J. (2007).
Use of hepatocytes to assess the con-
tribution of hepatic uptake to clear-
ance in vivo. Drug Metab. Dispos. 35,
859–865.
Takala, A., Kaasalainen, V., Seppälä,
T., Kalso, E., and Olkkola, K. T.
(1997). Pharmacokinetic compar-
ison of intravenous and intranasal
administration of oxycodone.
Acta Anaesthesiol. Scand. 41,
309–312.
Valentin, J. (ed.). (2003). Basic anatom-
ical and physiological data for use
in radiological protection: reference
values. Ann. ICRP Publication 89,
1–265.
Yang, J., Jamei, M., Yeo, K. R., Rostami-
Hodjegan, A., and Tucker, G. T.
(2007). Misuse of the well-stirred
model of hepatic drug clearance.
Drug Metab. Dispos. 35, 501–502.
Conﬂict of Interest Statement: An
unrestricted grant was received from
Mundipharma Oy, Vantaa, Finland, to
cover the costs of the chemicals.
Received: 19 October 2011; accepted: 16
December 2011; published online: 05 Jan-
uary 2012.
Citation: Korjamo T, Tolonen A, Ranta
V-P, Turpeinen M and Kokki H (2012)
Metabolism of oxycodone in human
hepatocytes from different age groups
and prediction of hepatic plasma clear-
ance. Front. Pharmacol. 2:87. doi:
10.3389/fphar.2011.00087
This article was submitted to Frontiers
in Drug Metabolism and Transport, a
specialty of Frontiers in Pharmacology.
Copyright © 2012 Korjamo, Tolonen,
Ranta, Turpeinen and Kokki. This is an
open-access article distributed under the
terms of the Creative Commons Attribu-
tion Non Commercial License, which per-
mits non-commercial use, distribution,
and reproduction in other forums, pro-
vided the original authors and source are
credited.
www.frontiersin.org January 2012 | Volume 2 | Article 87 | 7
